$SAGE
Sage Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023059750 Filed on November 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $77.97M $2.716M
YoY Change 2621.54% 56.18%
Cost Of Revenue $820.0K $900.0K
YoY Change 473.43% 389.13%
Gross Profit $77.15M $1.800M
YoY Change 2734.39% 15.76%
Gross Profit Margin 98.95% 66.27%
Selling, General & Admin $55.11M $78.14M
YoY Change -18.15% 27.1%
% of Gross Profit 71.43% 4341.22%
Research & Development $64.33M $101.9M
YoY Change -27.96% 24.97%
% of Gross Profit 83.38% 5662.17%
Depreciation & Amortization $393.0K $300.0K
YoY Change 35.52% 7.91%
% of Gross Profit 0.51% 16.67%
Operating Expenses $119.4M $214.6M
YoY Change -23.74% 49.82%
Operating Profit -$42.29M -$211.8M
YoY Change -72.52% 49.74%
Interest Expense $9.467M $10.27M
YoY Change 39.36% 148.95%
% of Operating Profit
Other Income/Expense, Net -$99.00K -$55.00K
YoY Change 167.57% -283.33%
Pretax Income -$32.71M -$201.6M
YoY Change -77.77% 46.81%
Income Tax
% Of Pretax Income
Net Earnings -$32.71M -$201.6M
YoY Change -77.77% 46.83%
Net Earnings / Revenue -41.95% -7423.78%
Basic Earnings Per Share -$3.37
Diluted Earnings Per Share -$0.55 -$3.37
COMMON SHARES
Basic Shares Outstanding 59.97M 59.88M
Diluted Shares Outstanding 59.91M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $753.2M $876.1M
YoY Change -40.81% -37.14%
Cash & Equivalents $70.99M $148.7M
Short-Term Investments $682.2M $727.3M
Other Short-Term Assets $33.16M $34.70M
YoY Change -34.76% -34.55%
Inventory
Prepaid Expenses
Receivables $83.01M $22.51M
Other Receivables $0.00 $0.00
Total Short-Term Assets $869.4M $933.3M
YoY Change -34.98% -36.3%
LONG-TERM ASSETS
Property, Plant & Equipment $1.921M $2.442M
YoY Change -33.71% -13.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.548M $6.593M
YoY Change 37.27% 34.3%
Total Long-Term Assets $12.93M $16.39M
YoY Change -33.6% -21.82%
TOTAL ASSETS
Total Short-Term Assets $869.4M $933.3M
Total Long-Term Assets $12.93M $16.39M
Total Assets $882.3M $949.7M
YoY Change -34.96% -36.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.32M $11.14M
YoY Change -45.55% 57.35%
Accrued Expenses $67.26M $114.9M
YoY Change -7.43% 35.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $82.75M $133.0M
YoY Change -16.64% 33.42%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $82.75M $133.0M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $82.75M $133.0M
YoY Change -20.32% 25.53%
SHAREHOLDERS EQUITY
Retained Earnings -$2.570B -$2.537B
YoY Change 28.48% 33.52%
Common Stock $3.370B $3.358B
YoY Change 2.4% 2.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $799.5M $816.7M
YoY Change
Total Liabilities & Shareholders Equity $882.3M $949.7M
YoY Change -34.96% -36.1%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$32.71M -$201.6M
YoY Change -77.77% 46.83%
Depreciation, Depletion And Amortization $393.0K $300.0K
YoY Change 35.52% 7.91%
Cash From Operating Activities -$119.5M -$135.9M
YoY Change -5.87% 14.33%
INVESTING ACTIVITIES
Capital Expenditures -$147.0K $400.0K
YoY Change -152.13% -209.89%
Acquisitions
YoY Change
Other Investing Activities $41.97M $160.7M
YoY Change -53.4% 44.36%
Cash From Investing Activities $42.01M $160.4M
YoY Change -53.2% 44.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -273.0K 2.800M
YoY Change -1041.38% 127.83%
NET CHANGE
Cash From Operating Activities -119.5M -135.9M
Cash From Investing Activities 42.01M 160.4M
Cash From Financing Activities -273.0K 2.800M
Net Change In Cash -77.74M 27.30M
YoY Change 109.41% -508.44%
FREE CASH FLOW
Cash From Operating Activities -$119.5M -$135.9M
Capital Expenditures -$147.0K $400.0K
Free Cash Flow -$119.3M -$136.3M
YoY Change -6.19% 15.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001597553
CY2022Q4 us-gaap Accounts Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration
AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q3 us-gaap Accounts Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration
AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36544
dei Entity Registrant Name
EntityRegistrantName
Sage Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4486580
dei Entity Address Address Line1
EntityAddressAddressLine1
215 First Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
299-8380
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
SAGE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59967516
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
148712000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
162700000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
727340000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1109794000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
34705000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
50826000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22513000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13660000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
933270000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1336980000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2442000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2898000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.51
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1332000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1269000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6026000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10532000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6593000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4770000
CY2023Q3 us-gaap Assets
Assets
949663000
CY2022Q4 us-gaap Assets
Assets
1356449000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
11136000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
18950000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
114901000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
72666000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6967000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7643000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
133004000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
99259000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4491000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
100000
CY2023Q3 us-gaap Liabilities
Liabilities
133004000
CY2022Q4 us-gaap Liabilities
Liabilities
103850000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59970549
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59512158
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59967516
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59509125
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
3033
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
3033
CY2023Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
400000
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
400000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3357741000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3291369000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2536953000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2028170000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3735000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10206000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
816659000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1252599000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
949663000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1356449000
CY2023Q3 us-gaap Revenues
Revenues
2716000
CY2022Q3 us-gaap Revenues
Revenues
1739000
us-gaap Revenues
Revenues
8483000
us-gaap Revenues
Revenues
4821000
CY2023Q3 sage Cost Of Sales
CostOfSales
905000
CY2022Q3 sage Cost Of Sales
CostOfSales
184000
sage Cost Of Sales
CostOfSales
1339000
sage Cost Of Sales
CostOfSales
670000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
101919000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
81553000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
291905000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
236868000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
78142000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
61482000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
219415000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
160370000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
33599000
us-gaap Restructuring Charges
RestructuringCharges
33599000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
214565000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
143219000
us-gaap Operating Expenses
OperatingExpenses
546258000
us-gaap Operating Expenses
OperatingExpenses
397908000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-211849000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-141480000
us-gaap Operating Income Loss
OperatingIncomeLoss
-537775000
us-gaap Operating Income Loss
OperatingIncomeLoss
-393087000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
10274000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4127000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
29276000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
7397000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-55000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
30000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-284000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
52000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-201630000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-137323000
us-gaap Net Income Loss
NetIncomeLoss
-508783000
us-gaap Net Income Loss
NetIncomeLoss
-385638000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.37
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.37
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.31
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.51
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59912378
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59912378
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59428123
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59428123
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59786254
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59786254
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59242563
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59242563
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-201630000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-137323000
us-gaap Net Income Loss
NetIncomeLoss
-508783000
us-gaap Net Income Loss
NetIncomeLoss
-385638000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1909000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1011000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6471000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-12223000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1909000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1011000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6471000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-12223000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-199721000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-138334000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-502312000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-397861000
us-gaap Profit Loss
ProfitLoss
-508783000
us-gaap Profit Loss
ProfitLoss
-385638000
us-gaap Share Based Compensation
ShareBasedCompensation
60422000
us-gaap Share Based Compensation
ShareBasedCompensation
46358000
sage Premium On Marketable Securities
PremiumOnMarketableSecurities
71000
sage Premium On Marketable Securities
PremiumOnMarketableSecurities
1464000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
12521000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-7182000
us-gaap Depreciation
Depreciation
984000
us-gaap Depreciation
Depreciation
832000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-16121000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13176000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
8853000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-58000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1823000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
658000
sage Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-4506000
sage Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-4139000
sage Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
-676000
sage Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
135000
sage Increase Decrease In Operating Lease Liabilities Non Current
IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent
-4491000
sage Increase Decrease In Operating Lease Liabilities Non Current
IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent
-4800000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-7677000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3357000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
41796000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
17285000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-421066000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-333104000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
861231000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
918816000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
459714000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
682505000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
665000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
655000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
400852000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
235656000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
6930000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3080000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
641000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
39000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6289000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3041000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13925000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-94407000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
163969000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
295502000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
150044000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
201095000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
54000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1729031000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
646000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1153000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18268000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-8541000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-122055000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1618502000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
37000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14652000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2671000
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-24000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-126260000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1504236000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
320000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1193000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12722000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1011000
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-15000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-137323000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1380122000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1252599000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
438000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2863000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19568000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
5118000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-629000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-146828000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1133129000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
855000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11281000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-556000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-8000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-160325000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
984376000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3656000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28352000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1909000
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-4000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-201630000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
816659000
CY2020 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
606100000
us-gaap Proceeds From Collaborators
ProceedsFromCollaborators
1000000000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3288804
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
34.63
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period</span><span style="color:#212529;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#212529;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
48900000
CY2023Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
147747000
CY2023Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
727340000
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
875087000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
161185000
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
1109794000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1270979000
CY2023Q3 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2022Q3 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
731075000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3737000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
727340000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1120000000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
44000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
10250000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1109794000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
511868000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
2088000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
158613000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
1649000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
670481000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
3737000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
513738000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
4795000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
399783000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
5455000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
913521000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
10250000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q3 sage Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
63386000
CY2022Q4 sage Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
32565000
CY2023Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
24250000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14108000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
29372000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
12497000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
10172000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
660000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
557000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
114901000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
72666000
CY2023Q3 sage Purchase Commitment Cancelling Excess Amount Committed
PurchaseCommitmentCancellingExcessAmountCommitted
28900000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
sage Share Based Compensation Arrangement By Share Based Payment Award Award Cliff Vesting Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod
P1Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11420766
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
7283210
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1415481
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
48.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
2594486
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
30.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
236852
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
56.32
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
484311
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
43.37
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28691000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13169000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60422000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
46358000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28691000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13169000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60422000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
46358000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
30.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
25.96
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-201630000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-137323000
us-gaap Net Income Loss
NetIncomeLoss
-508783000
us-gaap Net Income Loss
NetIncomeLoss
-385638000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59912378
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59912378
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59428123
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59428123
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59786254
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59786254
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59242563
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59242563
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.37
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.37
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.31
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.51
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9423915
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7241426
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9423915
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7241426
CY2023Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.40
CY2023Q3 us-gaap Restructuring Costs
RestructuringCosts
33600000
us-gaap Restructuring And Related Cost Incurred Cost
RestructuringAndRelatedCostIncurredCost
36900000
CY2023Q3 us-gaap Restructuring And Related Cost Expected Cost Remaining1
RestructuringAndRelatedCostExpectedCostRemaining1
3300000
CY2023Q2 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
33599000
CY2023Q3 us-gaap Payments For Restructuring
PaymentsForRestructuring
5715000
CY2023Q3 us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
3634000
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
24250000
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-23-059750-index-headers.html Edgar Link pending
0000950170-23-059750-index.html Edgar Link pending
0000950170-23-059750.txt Edgar Link pending
0000950170-23-059750-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img93204646_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sage-20230930.htm Edgar Link pending
sage-20230930.xsd Edgar Link pending
sage-ex10_1.htm Edgar Link pending
sage-ex10_2.htm Edgar Link pending
sage-ex31_1.htm Edgar Link pending
sage-ex31_2.htm Edgar Link pending
sage-ex32_1.htm Edgar Link pending
Show.js Edgar Link pending
sage-20230930_def.xml Edgar Link unprocessable
sage-20230930_pre.xml Edgar Link unprocessable
sage-20230930_cal.xml Edgar Link unprocessable
sage-20230930_lab.xml Edgar Link unprocessable
sage-20230930_htm.xml Edgar Link completed